Septerna (SEPN) Stock: Buy, Sell, or Hold?
SEPN - Septerna, Inc. Common Stock
$37.71
-0.34 (-0.89%)
âŧ
5d:
-0.16%
30d:
+0.56%
90d:
+12.67%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 09, 2026
Get Alerted When SEPN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SEPN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SEPN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SEPN is currently trading at $37.71, which is considered slightly low relative to its 30-day fair value range of $37.55 to $39.83.
Technical Outlook: Technically, SEPN is in a uptrend. The price is currently testing key support at $36.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SEPN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.22 (+43.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SEPN is in a uptrend. The price is currently testing key support at $36.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SEPN scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $54.22 (+43.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$37.55 -
$39.83
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.8% below Wall St target ($54.22)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$37.55 -
$39.83
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$36.98
Resistance Level
$41.09
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.43
Wall Street Target
$54.22
(+43.8%)
Revenue Growth (YoY)
22375.6%
Profit Margin
-24.5%
Share & Embed Analysis
Last updated: October 02, 2026 9:44 PM ET
Data refreshes hourly during market hours. Next update: 10:44 PM
Data refreshes hourly during market hours. Next update: 10:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SEPN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Elizabeth Bhatt
SELL
4000 shares
2026-04-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 68 BUY |
